Your browser doesn't support javascript.
loading
Digoxin as an emerging therapy in noncardiac diseases.
Dashti, Farzaneh; Jamshed, Fatima; Ouyang, Xinshou; Mehal, Wajahat Z; Banini, Bubu A.
Afiliación
  • Dashti F; Section of Digestive Diseases, Yale School of Medicine, PO Box 208019, New Haven, CT 06520, USA.
  • Jamshed F; Section of Digestive Diseases, Yale School of Medicine, PO Box 208019, New Haven, CT 06520, USA; Griffin Hospital-Yale University, 130 Division Street, Derby, CT 06418, USA.
  • Ouyang X; Section of Digestive Diseases, Yale School of Medicine, PO Box 208019, New Haven, CT 06520, USA.
  • Mehal WZ; Section of Digestive Diseases, Yale School of Medicine, PO Box 208019, New Haven, CT 06520, USA; West Haven Veterans Medical Center, West Haven, CT 06516, USA.
  • Banini BA; Section of Digestive Diseases, Yale School of Medicine, PO Box 208019, New Haven, CT 06520, USA. Electronic address: bubu.banini@yale.edu.
Trends Pharmacol Sci ; 44(4): 199-203, 2023 04.
Article en En | MEDLINE | ID: mdl-36396496
ABSTRACT
The cardiac glycoside (CG) digoxin is a generic drug approved for the treatment of heart failure and supraventricular arrhythmias. Over the past few decades, substantial strides have been made toward repurposing digoxin to treat various noncardiac diseases. Here, we evaluate recent insights into basic and clinical work related to noncardiac use of digoxin.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Glicósidos Cardíacos / Insuficiencia Cardíaca Límite: Humans Idioma: En Revista: Trends Pharmacol Sci Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Glicósidos Cardíacos / Insuficiencia Cardíaca Límite: Humans Idioma: En Revista: Trends Pharmacol Sci Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos